DrugPatentWatch Database Preview
Investigational Drug Information for ND0612
Email this page to a colleague
What is the drug development status for ND0612?
ND0612 is an investigational drug.
There have been 9 clinical trials for ND0612.
The most recent clinical trial was a Phase 2 trial, which was initiated on August 27th 2019.
The most common disease conditions in clinical trials are Parkinson Disease and [disabled in preview]. The leading clinical trial sponsors are NeuroDerm Ltd., Michael J. Fox Foundation for Parkinson's Research, and Quotient Clinical.
There are two hundred and forty-nine US patents protecting this investigational drug and two international patents.
Summary for ND0612
| US Patents | 249 |
| International Patents | 2,830 |
| US Patent Applications | 884 |
| WIPO Patent Applications | 575 |
| Japanese Patent Applications | 351 |
| Clinical Trial Progress | Phase 2 (2019-08-27) |
| Vendors | 3 |
Recent Clinical Trials for ND0612
| Title | Sponsor | Phase |
|---|---|---|
| A Clinical Trial Investigating the Efficacy, Safety and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless). | NeuroDerm Ltd. | Phase 3 |
| A Clinical Study Investigating the Efficacy, Tolerability, and Safety of Continuous Subcutaneous ND0612 Infusion Given as Adjunct Treatment to Oral Levodopa in Patients With Parkinson's Disease With Motor Fluctuations | NeuroDerm Ltd. | Phase 3 |
| A Clinical Study in Advanced Parkinson's Disease Investigating the Long Term Safety of ND0612 Administered as a Continuous SC Infusion | NeuroDerm Ltd. | Phase 2 |
Clinical Trial Summary for ND0612
Top disease conditions for ND0612
Top clinical trial sponsors for ND0612
US Patents for ND0612
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| ND0612 | ⤷ Try it Free | Dopa decarboxylase inhibitor compositions | NeuroDerm, Ltd. (Rehovot, IL) | ⤷ Try it Free |
| ND0612 | ⤷ Try it Free | Human anti-IL-23 antibodies, compositions, methods and uses | Janssen Biotech, Inc. (Horsham, PA) | ⤷ Try it Free |
| ND0612 | ⤷ Try it Free | Fibronectin type III domain based scaffold compositions, methods and uses | Janssen Biotech, Inc. (Horsham, PA) | ⤷ Try it Free |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for ND0612
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| ND0612 | Australia | AU2015228369 | 2034-03-13 | ⤷ Try it Free |
| ND0612 | Brazil | BR112016021034 | 2034-03-13 | ⤷ Try it Free |
| ND0612 | Canada | CA2942244 | 2034-03-13 | ⤷ Try it Free |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
